The start of a potentially big biomedical breakthrough is blooming within all of us. Drug research aiming to turn bacteria into microbiome therapies now spans programs aiming to address gut disorders, autism, cancer, and more. Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the … Continue reading “Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)”
Category: Boston
New COVID-19 Special Reports Explore Clinical Research During the Pandemic
Two new special reports on Xconomy Insight provide an expert view on how companies can sustain clinical trials during the COVID-19 crisis. “Decentralized Clinical Trials: The Call for a New Paradigm” and “Sustaining Clinical Research During the Crisis” offer the latest trends and technologies companies can use to keep business running as smooth as possible. … Continue reading “New COVID-19 Special Reports Explore Clinical Research During the Pandemic”
War Paint to Bone Paint: MIT Spinout Aims to Transform Regenerative Meds
Driven by 20 years in the military, the founder of Theradaptive hopes his firm’s regenerative “paint” technology platform can transform bone repair, spinal fusion, and sports medicine. The firm, spun out of MIT, has a computational platform it says turns recombinant proteins into material-binding variants that behave like a paint. This can then be used … Continue reading “War Paint to Bone Paint: MIT Spinout Aims to Transform Regenerative Meds”
Ohana Bio Adds Ramiro Castro-Santamaria as Chief Medical Officer
Ohana Biosciences announced it appointed Ramiro Castro-Santamaria, a urologist and family medicine physician, as its chief medical officer. Castro-Santamaria was most recently vice president of clinical sciences and head of rheumatology at GlaxoSmithKline (NYSE: [[ticker:GSK]]), where he spent 14 years serving in various clinical development and R&D roles. His prior experience includes roles at Boehringer … Continue reading “Ohana Bio Adds Ramiro Castro-Santamaria as Chief Medical Officer”
COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market
If Peter Marks had a magic wand to perfect the sophisticated process that takes a new vaccine from idea to reality, the US could have a way to prevent some people from COVID-19 infection in nine months to one year. In the real world, the journey to a vaccine OK’d under emergency guidelines is more … Continue reading “COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market”
Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More
The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: [[ticker:ALNY]]) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol. Alnylam had sold the drug’s development and commercialization … Continue reading “Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More”
TearClear Taps Former Shire Executive Robert Dempsey as CEO
Eye drug developer TearClear has appointed Robert Dempsey to serve as its CEO. Demsey was most recently global head of ophthalmology at Shire, which was acquired by Takeda Pharmaceutical (NYSE: [[ticker:TAK]]). TearClear says Dempsey’s hire comes as the company approaches the initial close of a Series B round of funding that could reach up to … Continue reading “TearClear Taps Former Shire Executive Robert Dempsey as CEO”
Neurology at Forefront of FDA’s Complex Innovative Trial Design Pilot
The coronavirus pandemic has frozen many clinical trials and forced others to adapt in the face of overwhelmed healthcare systems around the world. When activity resumes, trials could look different, with more remote monitoring and decentralized enrollment. They could reflect some of the design evolutions that the US Food and Drug Administration and sponsors have … Continue reading “Neurology at Forefront of FDA’s Complex Innovative Trial Design Pilot”
Ex-Regeneron Exec Graham Named Evelo Bio Chief Development Officer
Neil Graham has joined Evelo Biosciences (NASDAQ: [[ticker:EVLO]]) as its chief development officer. He was most recently vice president of immunology and inflammation at Regeneron Pharmaceuticals (NASDAQ: [[ticker:REGN]]). Graham’s experience also includes positions at Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]) and Trimeris. Evelo is developing oral biologic drugs that address the small intestinal axis, which plays a … Continue reading “Ex-Regeneron Exec Graham Named Evelo Bio Chief Development Officer”
With Harvard Tech and $5M, PIC Therapeutics Takes Aim at Cancer
Some of the targets in cancer research are visible and well known, but they’re hard to hit with new drugs all the same. PIC Therapeutics is developing medicines aiming for one particularly elusive group of proteins, and the startup’s early research has attracted financial support from some prominent names in the life sciences industry. PIC … Continue reading “With Harvard Tech and $5M, PIC Therapeutics Takes Aim at Cancer”
Cerevance Raises $45M to Advance Brain Disease Research & Development
Cerevance, a biotech focused on developing new treatments for brain diseases, has added $45 million to its coffers in a Series B financing round from investors including the venture capital arm of Google parent company Alphabet and billionaire philanthropist Bill Gates. On Tuesday the Boston-based company said the money would allow it to continue identifying … Continue reading “Cerevance Raises $45M to Advance Brain Disease Research & Development”
GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year
[Updated, 3:13 p.m. See below.] Pharmaceutical giants GlaxoSmithKline and Sanofi are teaming up on COVID-19 research, aiming to combine their respective technologies in a new vaccine that could start clinical trials in coming months. The full details of the agreement, which was announced Tuesday, are still being finalized. But the companies say the vaccine would … Continue reading “GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year”
Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran
Seven years ago Alnylam Pharmaceuticals sold rights to one of its preclinical drugs, gaining upfront cash and $180 million in potential milestone payments, plus royalties, for a therapy taking a novel approach to lowering cholesterol. On Monday, the company announced the sale of half of the royalties it’s owed to private equity firm Blackstone for … Continue reading “Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran”
Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data
Akero’s FGF21 analog yields 63 percent to 72 percent relative hepatic fat reduction in Phase 2a study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase 3 NASH readout. FGF21 analogs comprise one of the more crowded classes in nonalcoholic steatohepatitis (NASH) … Continue reading “Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data”
Tango Therapeutics Appoints Beckman as Chief Financial Officer
Daniella Beckman is now the permanent chief financial officer of Tango Therapeutics after holding the role in an interim capacity. Her experience includes financial positions at Idenix Pharmaceuticals, Coley Pharmaceuticals, Biogen Idec, and PricewaterhouseCoopers. Cambridge, MA-based Tango recently raised $60 million in Series B financing to support continued development of cancer drugs based on a … Continue reading “Tango Therapeutics Appoints Beckman as Chief Financial Officer”
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences sector. The coronavirus research is expected. It’s the other activity that might come as a surprise. Two biotech companies have gone public in the past week; each upsized its offering and … Continue reading “Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More”
Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month
Multiple COVID-19 vaccine candidates that use a new technology called messenger RNA are now being readied for clinical trials that Pfizer and BioNTech plan to start in coming weeks. The partnership pairs the mRNA vaccine technology of BioNTech (NASDAQ: [[ticker:BNTX]]) with the vaccine and clinical trial experience of Pfizer (NYSE: [[ticker:PFE]]). The companies said Thursday … Continue reading “Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month”
Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs
CRISPR is key to the cancer drugs that Tango Therapeutics is developing, but the startup isn’t out to edit disease-causing genes. Tango uses the technology as a tool for finding drug targets, in research that has yielded a pipeline of compounds. Now it has $60 million to continue that work. The Series B round of … Continue reading “Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs”
Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics
Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis Therapeutics, a startup whose technology aims for RNA—carriers of the genetic instructions that make these proteins in the first place. The cash, an upfront payment to Waltham, MA-based Arrakis, … Continue reading “Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics”
Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests
The financial markets may remain volatile but Keros Therapeutics (NASDAQ: [[ticker:KROS]]) managed to raise more money in its public market debut than it had initially planned. Late Tuesday, the Lexington, MA-based company offered 6 million shares for $16 apiece, the high end of its projected price range. Keros had previously planned to offer 5 million … Continue reading “Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests”
Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers
Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA’s OK to start testing its candidate in healthy volunteers. The Plymouth Meeting, PA-based company, which also conducts research in San Diego, plans to enroll as many as 40 adults across two trial locations. Inovio (NASDAQ: [[ticker:INO]]) said Monday it … Continue reading “Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers”
Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug
Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including a depression treatment that failed a pivotal test late last year. The corporate shakeup will eliminate the jobs of 340 employees, or about 53 percent of its staff, Sage … Continue reading “Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug”
Morphic Appoints ArQule’s Schegerin Chief Financial, Operating Officer
Morphic Therapeutic (NASDAQ: [[ticker:MORF]]) has named Marc Schegerin as its chief financial officer and chief operating officer. Schegerin was most recently CFO at cancer drug developer ArQule, which Merck (NYSE: [[ticker:MRK]]) agreed to acquire in December for $2.7 billion. Schegerin joins another recent addition to Morphic’s C suite, Peter Linde, who joined the company in … Continue reading “Morphic Appoints ArQule’s Schegerin Chief Financial, Operating Officer”
Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13
In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us May 13, 2020 for our Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health interactive online event to learn the latest trends, and network with leading entrepreneurs, scientists, and investors. Agenda includes expert … Continue reading “Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13”
Seres Therapeutics Taps Alkermes’s von Moltke as Chief Medical Officer
Seres Therapeutics (NASDAQ: [[ticker:MCRB]]) has appointed Lisa von Moltke to serve as its executive vice president and chief medical officer. She is joining the Cambridge, MA-based microbiome drug developer from Alkermes (NASDAQ: [[ticker:ALKS]]), where she was senior vice president and head of clinical development. Her experience also includes positions at Sanofi (NYSE: [[ticker:SNY]]) and Takeda … Continue reading “Seres Therapeutics Taps Alkermes’s von Moltke as Chief Medical Officer”
GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months
GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two experimental therapies to clinical testing this summer. The partnership will leverage antibody technology from Vir (NASDAQ: [[ticker:VIR]]) and genomics expertise from GSK (NYSE: [[ticker:GSK]]). The companies will work together … Continue reading “GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months”
Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment
Based on the latest news and analysis, as well as conversations from industry experts during the Combatting Coronavirus live panel at BIO-Europe Spring®, Xconomy’s free special report delivers the latest COVID-19 news from the frontlines as top biotech and investment players offer their best plans and current progress in stemming and ultimately defeating the current … Continue reading “Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment”
Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More
The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3 billion. ARCH Venture Partners led the pack, adding two funds totaling $1.46 billion to its war chest. Flagship Pioneering bagged $1.1 billion, and venBio Partners reeled in $394 million. Flagship CEO Noubar … Continue reading “Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More”
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs
Investors worried about a recession like venBio Partners’ risk-mitigated approach to venture capital investing. That approach has led new limited partners to join earlier backers in putting nearly $400 million into the San Francisco-based firm’s new fund. VenBio announced Friday it closed its third fund, raising $394 million which it plans to invest using the … Continue reading “VenBio Partners Bags $394M to Back More Medicine-Making Biotechs”
Flagship Adds $1.1B for New Meds, More AI, & “Health Security”
Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall. One proved eerily prescient: The notion of “health security,” or the development of new products and therapies to treat … Continue reading “Flagship Adds $1.1B for New Meds, More AI, & “Health Security””
Iteos Therapeutics Adds $125M to Advance Next-Gen Immunotherapies
Immunotherapies called checkpoint inhibitors have helped change the way a number of cancers are treated by blocking a tumor cell’s ability to hide from the immune system. Some patients don’t respond, however, or develop resistance to these drugs. Iteos Therapeutics has raised $125 million to advance new cancer treatments it is developing to target two … Continue reading “Iteos Therapeutics Adds $125M to Advance Next-Gen Immunotherapies”
Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic
Pandion Therapeutics emerged in 2018 aiming to reach clinic trials in two years testing its biologic drugs in autoimmune and inflammatory disorders. The company now has $80 million to support a lead program in early-stage testing and a pipeline of potential treatments. Access Biotechnology and Boxer Capital led the Series B round of funding announced … Continue reading “Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic”
Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO
Hunter Smith, chief financial officer of Rhythm Pharmaceuticals (NASDAQ: [[ticker:RYTM]]), has been appointed interim CEO. He takes the place of Keith Gottesdiener, who announced in January that he planned to leave his executive positions and the board of directors after Rhythm submitted a new drug application for setmelanotide. The application was filed with the FDA … Continue reading “Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO”
A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy
[Updated 4/10/2020, 3:24 p.m. See below.] Cameron Hewitt’s family celebrates the anniversary of her life not once, but twice yearly: Besides her September birthday, they commemorate a day in March—the anniversary of two-year-old Cameron receiving the gene therapy that gave her a new shot at life. Cameron was born with spinal muscular atrophy (SMA), a … Continue reading “A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy”
Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance
Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that treat a disease or spark immunity to one. Sanofi (NYSE: [[ticker:SNY]]) announced Friday that it will develop COVID-19 vaccine candidates with Translate Bio (NASDAQ: [[ticker:TBIO]]), … Continue reading “Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance”
Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More
Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible. Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. Eli Lilly (NYSE: [[ticker:LLY]]) said that … Continue reading “Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More”
Fusion Pharmaceuticals Taps James O’Leary as Chief Medical Officer
Fusion Pharmaceuticals has appointed James O’Leary as its chief medical officer. O’Leary’s experience includes roles at ImmunoGen (NASDAQ: [[ticker:IMGN]]), Idera Pharmaceuticals (NASDAQ: [[ticker:IDRA]]), Array Biopharma, and Deciphera (NASDAQ: [[ticker:DCPH]]), Takeda (NYSE: [[ticker:TAK]]), Bayer, and Pfizer (NYSE: [[ticker:PFE]]). Most recently O’Leary was a global project team leader for a late-stage asset directing global strategy and regulatory … Continue reading “Fusion Pharmaceuticals Taps James O’Leary as Chief Medical Officer”
Akcea Therapeutics Promotes Damien McDevitt to CEO
Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) has appointed Damien McDevitt as its chief executive officer. McDevitt had been serving as the Boston company’s interim CEO since September 2019, when CEO Paula Soteropoulos, president Sarah Boyce, and chief operating officer Jeff Goldberg left in a sudden management shakeup. Akcea is advancing a group of experimental rare disease drugs discovered by … Continue reading “Akcea Therapeutics Promotes Damien McDevitt to CEO”
Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel
Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs. That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade” recorded for the BIO-Europe Spring partnering conference. The event is produced by EBD Group, … Continue reading “Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel”
Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments
Regenacy Pharmaceuticals, a biotech formed as part of Celgene’s acquisition of Acetylon Pharmaceuticals in late 2016, has raised $30 million in Series A financing to move its lead program into a Phase 2 proof-of-concept trial this year. The Waltham, MA-based company is developing treatments to address the underlying cause of peripheral neuropathies—a form of nerve … Continue reading “Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments”
AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics
After years of research, technology for silencing a gene—stopping it from producing a disease-causing protein—has reached patients. AstraZeneca is now angling for a position in this burgeoning field through an alliance with Silence Therapeutics, a biotech developing such gene-silencing drugs. According to deal terms announced Wednesday, AstraZeneca (NYSE: [[ticker:AZN]]) will pay London-based Silence (LON: [[ticker:SLN]]) … Continue reading “AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics”
Epizyme Names Infinity’s Jeffery Kutok as Chief Scientific Officer
Epizyme (NASDAQ: [[ticker:EPZM]]) has appointed Jeffery Kutok as its chief scientific officer to guide the Cambridge, MA-based company’s scientific strategy following the FDA’s approval earlier this year of its first drug as a treatment for epithelioid sarcoma. Kutok was most recently executive vice president and chief scientific officer at Infinity Pharmaceuticals (NASDAQ: [[ticker:INFI]]), which is also based in … Continue reading “Epizyme Names Infinity’s Jeffery Kutok as Chief Scientific Officer”
Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown
The coronavirus pandemic is narrowing the avenues open to biotechs for financing their endeavors, according to some industry veterans. “I think that fear of losing out has pretty much gone out the window right now,” said Equillium (NASDAQ: [[ticker:EQ]]) CEO Bruce Steel in a phone interview with Xconomy, speaking generally of investor appetite. “I think … Continue reading “Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown”
Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic
Keros Therapeutics, a biotech which raised more than $50 million this month in venture capital, is now looking to tap the public markets for additional cash amid a time of historic tumult. The Lexington, MA-based company, is a clinical-stage biotech that aims to develop new treatments for patients with blood and musculoskeletal disorders by developing … Continue reading “Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic”
Emulate Taps PerkinElmer’s Corbett as CEO, Gets Cash for Commercial Push
“Organ-on-a-chip” startup Emulate has appointed Jim Corbett to serve as its new CEO. Corbett joins the Boston-based company from PerkinElmer, where he was executive vice president and president of discovery & analytical solutions. At Emulate, he succeeds founding CEO James Coon. Emulate has developed tiny chips lined with human cells that can be used to … Continue reading “Emulate Taps PerkinElmer’s Corbett as CEO, Gets Cash for Commercial Push”
Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More
The past week brought a sea change in many of our daily lives as the impact of the continued spread of the novel coronavirus altered how we work and play as communities around the world attempt to slow its spread. Xconomy, as always, is focused on the stories coming out of the life sciences community. … Continue reading “Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More”
As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future
The following sponsored content was submitted by commercial real estate brokerage firm Hughes Marino: The story of the “canary in the coal mine” is an advanced warning of danger. The metaphor originates from when miners used to carry caged canaries while at work; if the air in the mine became toxic, the canary would die … Continue reading “As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future”
Morphic Appoints Acceleron’s Peter Linde as Its Chief Medical Officer
Morphic Therapeutic (NASDAQ: [[ticker:MORF]]) on Tuesday named Peter Linde as its chief medical officer. Linde was most recently vice president of medical research at Acceleron Pharma (NASDAQ: [[ticker:XLRN]]), where he oversaw the design and execution of clinical trials including late-stage development work on luspatercept, a drug the FDA approved last year for patients with the … Continue reading “Morphic Appoints Acceleron’s Peter Linde as Its Chief Medical Officer”
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More
The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but not in any way that people wanted or expected. The World Health Organization this week declared that the COVID-19 outbreak was serious enough to classify as pandemic. The toll on public health … Continue reading “Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More”
Repertoire Immune Taps Torque Top Exec, Biogen Vet John Cox as CEO
Repertoire Immune Medicines, a Cambridge, MA-based biotech Flagship Pioneering formed by combining its companies Cogen Immune Medicines and Torque Therapeutics, named John Cox its CEO. Cox has been Torque’s chief executive since late 2019. Previously Cox was the CEO of Bioverativ (NASDAQ: [[ticker:BIIV]]), which he spun out from Biogen (NASDAQ: [[ticker:BIIB]]) in 2016 and oversaw … Continue reading “Repertoire Immune Taps Torque Top Exec, Biogen Vet John Cox as CEO”